UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049951
Receipt number R000056891
Scientific Title Self-controlled, open-label, pre/post comparison study of functional supplements to characterize changes in SAF and study on population with reduced SAF
Date of disclosure of the study information 2023/04/01
Last modified on 2023/01/01 11:11:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on reduction of skin autofluorescence (SAF) by various supplements

Acronym

Decrease in SAF by taking supplements

Scientific Title

Self-controlled, open-label, pre/post comparison study of functional supplements to characterize changes in SAF and study on population with reduced SAF

Scientific Title:Acronym

Research on individuals showing reduction of SAF by taking supplements

Region

Japan


Condition

Condition

Advanced glycation end-products

Classification by specialty

Geriatrics Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

Individualized study of response to supplements in subjects with elevated SAF value

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of the difference between the mean SAF at the end of the last week (week 20) of supplementation and the mean SAF during the previous observation period (1-2 weeks) in individual subjects

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Hydrogen-releasing supplements for 20 weeks or
Reduced form of CoQ10 for 20 weeks or
Foods containing Salacia ingredients for 20 weeks or
Foods containing mulberry leaf ingredients for 20 weeks or
Foods containing mangosteen ingredients for 20 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Those who have at least 1 S.D. above the mean SAF for the subject's age at the time of screening prior to obtaining consent
2. Those who are 20 years-old or older at the time of obtaining consent
3. Those who have given their free written consent after receiving sufficient explanation for participation in this research

Key exclusion criteria

1. Those who are below the SAF average for the subject's age, or those who are above the average but below 1 S.D. at the time of screening prior to obtaining consent
2. Those who have a SAF value variation of more than plus/minus 0.2 a.u. from the SAF value at screening during the previous observation period
3. Those who are 70 years-old or older, BMI 30 or higher, and current smoker at the time of consent
4. Those who suspected alcohol or caffeine addiction
5. Those who with extremely irregular lifestyle
6. Those who have history of cardiovascular disease (males only), diabetes mellitus, or renal failure (on dialysis)
7. Patients with severe renal disease (more than BUN 25 mg/dL or serum creatinine 2.0 mg/dL)
8. Patients with severe liver disease (more than AST (GOT) or ALT (GPT) 100 U)
9. Pregnant or possibly pregnant or lactating women
10. Those who are drug addiction
11. Individuals who are deemed inappropriate as research participants by the principal investigator

Target sample size

180


Research contact person

Name of lead principal investigator

1st name Noritaka
Middle name
Last name Ariyoshi

Organization

Okayama University

Division name

Facylty of Medicine, Dentistry and Pharmaceutical Sciences

Zip code

7008558

Address

2-5-1 Shikata-cho, Kita-ku, Okayama, Japan

TEL

086-235-6619

Email

ariyoshi-n@okayama-u.ac.jp


Public contact

Name of contact person

1st name Noritaka
Middle name
Last name Ariyoshi

Organization

Okayama University

Division name

Faculty of Medicine, Dentistry and Pharmaceutical Sciences

Zip code

7008558

Address

2-5-1 Shikata-cho, Kita-ku, Okayama, Japan

TEL

086-235-6619

Homepage URL


Email

pmaphs.ou@gmail.com


Sponsor or person

Institute

Okayama University

Institute

Department

Personal name



Funding Source

Organization

Okayama University

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical Research Ethics Committee, Faculty of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital

Address

2-5-1 Shikata-cho, Kita-ku, Okayama, Japan

Tel

086-235-6938

Email

mae6605@adm.okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 12 Month 31 Day

Date of IRB


Anticipated trial start date

2023 Year 03 Month 31 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 01 Month 01 Day

Last modified on

2023 Year 01 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056891


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name